Gan & Lee Pharmaceuticals. (603087.SS)
CNY 44.27
(1.26%)
CNY 44.27
(1.26%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 11.71 Billion CNY | 10.45% |
| 2022 | 10.6 Billion CNY | -2.27% |
| 2021 | 10.85 Billion CNY | 14.15% |
| 2020 | 9.5 Billion CNY | 57.76% |
| 2019 | 6.02 Billion CNY | 28.37% |
| 2018 | 4.69 Billion CNY | 25.42% |
| 2017 | 3.74 Billion CNY | 43.76% |
| 2016 | 2.6 Billion CNY | 43.77% |
| 2015 | 1.81 Billion CNY | 50.62% |
| 2014 | 1.2 Billion CNY | 44.43% |
| 2013 | 832.54 Million CNY | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q1 | 11.71 Billion CNY | 0.04% |
| 2024 Q3 | 12.22 Billion CNY | 2.25% |
| 2024 Q2 | 11.95 Billion CNY | 1.98% |
| 2023 FY | 11.71 Billion CNY | 10.45% |
| 2023 Q1 | 10.59 Billion CNY | -0.1% |
| 2023 Q3 | 10.82 Billion CNY | 0.89% |
| 2023 Q4 | 11.71 Billion CNY | 8.22% |
| 2023 Q2 | 10.72 Billion CNY | 1.26% |
| 2022 Q3 | 10.4 Billion CNY | -0.17% |
| 2022 Q1 | 10.91 Billion CNY | 0.59% |
| 2022 FY | 10.6 Billion CNY | -2.27% |
| 2022 Q4 | 10.6 Billion CNY | 1.99% |
| 2022 Q2 | 10.41 Billion CNY | -4.57% |
| 2021 Q1 | 9.64 Billion CNY | 1.47% |
| 2021 Q3 | 10.25 Billion CNY | 4.22% |
| 2021 Q2 | 9.84 Billion CNY | 2.01% |
| 2021 Q4 | 10.85 Billion CNY | 5.82% |
| 2021 FY | 10.85 Billion CNY | 14.15% |
| 2020 Q3 | 9.03 Billion CNY | 3.37% |
| 2020 FY | 9.5 Billion CNY | 57.76% |
| 2020 Q1 | 6 Billion CNY | -0.37% |
| 2020 Q4 | 9.5 Billion CNY | 5.28% |
| 2020 Q2 | 8.73 Billion CNY | 45.5% |
| 2019 FY | 6.02 Billion CNY | 28.37% |
| 2019 Q1 | - CNY | 0.0% |
| 2019 Q4 | 6.02 Billion CNY | 0.0% |
| 2018 FY | 4.69 Billion CNY | 25.42% |
| 2017 Q1 | 2.96 Billion CNY | 0.0% |
| 2017 FY | 3.74 Billion CNY | 43.76% |
| 2017 Q4 | 3.74 Billion CNY | 0.0% |
| 2017 Q2 | 2.96 Billion CNY | 0.0% |
| 2016 FY | 2.6 Billion CNY | 43.77% |
| 2015 FY | 1.81 Billion CNY | 50.62% |
| 2014 FY | 1.2 Billion CNY | 44.43% |
| 2013 FY | 832.54 Million CNY | 0.0% |